Randomized-controlled study of isophane and aspart insulin versus glargine and aspart insulin to treat prednisolone-induced hyperglycaemia in hospitalized patients

被引：0
|
作者：
Radhakutty, Anjana [1 ,2 ,3 ]
Stranks, Jessica L. [1 ]
Mangelsdorf, Brenda L. [1 ]
Drake, Sophie M. [1 ]
Roberts, Gregory W. [3 ,4 ]
Zimmermann, Anthony [2 ]
Stranks, Stephen N. [1 ]
Thompson, Campbell H. [3 ,5 ]
Burt, Morton G. [1 ,3 ]
机构：
[1] Repatriat Gen Hosp, Southern Adelaide Diabet & Endocrine Serv, Adelaide, SA, Australia
[2] Lyell McEwin Hosp, Endocrinol, Adelaide, SA, Australia
[3] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia
[4] Flinders Med Ctr, Dept Pharm, Adelaide, SA, Australia
[5] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
来源：
CLINICAL ENDOCRINOLOGY | 2017年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [41] NPH Insulin Versus Insulin Glargine Versus NPH Insulin Plus Insulin Glargine for the Treatment of Dexamethasone-Induced Hyperglycemia in Patients With COVID-19: A Retrospective Cohort Study
    Fornwald, Courtney R. R.
    Tuttle, Natalie S. S.
    Murphy, Julie A. A.
    JOURNAL OF PHARMACY TECHNOLOGY, 2023, 39 (02) : 68 - 74
  • [42] The SimpleMix study with biphasic insulin aspart 30: a randomized controlled trial investigating patient-driven titration versus investigator-driven titration
    Gao, Yan
    Luquez, Cecilia
    Lynggaard, Helle
    Andersen, Henning
    Saboo, Banshi
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (12) : 2483 - 2492
  • [43] Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study
    Nagai, Yoshio
    Nishine, Ami
    Hashimoto, Eriko
    Nakayama, Taiga
    Sasaki, Yosuke
    Murakami, Mariko
    Ishii, Satoshi
    Kato, Hiroyuki
    Tanaka, Yasushi
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (03): : 567 - 572
  • [44] Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
    Blevins, Thomas C.
    Raiter, Yaron
    Sun, Bin
    Donnelly, Charles
    Shapiro, Roxann
    Chullikana, Anoop
    Rao, Anita
    Vashishta, Laxmikant
    Ranganna, Gopinath
    Barve, Abhijit
    BIODRUGS, 2022, 36 (06) : 761 - 772
  • [45] Glargine Insulin Use Versus Continuous Regular Insulin in Diabetic Surgical Noncritically Ill Patients Receiving Parenteral Nutrition: Randomized Controlled Study
    Hakeam, Hakeam A.
    Mulia, Hamdy A.
    Azzam, Ayman
    Amin, Tarek
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2017, 41 (07) : 1110 - 1118
  • [46] Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widel, MH
    Brodows, RG
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (08) : 559 - 569
  • [47] Efficacy and Safety of Biphasic Insulin Aspart Treatment in Hospitalized Patients with T2DM-A Real-World Study
    Erukulapati, Ravi S.
    Yerramilli, Aparna
    Kancherla, Visalakshi
    Sreelalitha, Gopala Rao S.
    Poojari, Anitha
    Khan, Fathima Z.
    Chappidi, Krishna Reddy
    DIABETES, 2018, 67
  • [48] A COMPARISON OF TWICE-DAILY BIPHASIC INSULIN ASPART 70/30 AND ONCE-DAILY INSULIN GLARGINE IN PERSONS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON BASAL INSULIN AND ORAL THERAPY: A RANDOMIZED, OPEN-LABEL STUDY
    Ligthelm, Robert J.
    Gylvin, Titus
    DeLuzio, Tony
    Raskin, Philip
    ENDOCRINE PRACTICE, 2011, 17 (01) : 41 - 50
  • [49] Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
    Thomas C. Blevins
    Yaron Raiter
    Bin Sun
    Charles Donnelly
    Roxann Shapiro
    Anoop Chullikana
    Anita Rao
    Laxmikant Vashishta
    Gopinath Ranganna
    Abhijit Barve
    BioDrugs, 2022, 36 : 761 - 772
  • [50] Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial
    Shaoyong Xu
    Xiangyang Liu
    Jie Ming
    Qiuhe Ji
    Trials, 17
12345